Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Mir-504 Expression Level Is Increased in Multiple Sclerosis Patients Responder to Interferon-Beta Publisher Pubmed



Tahmasebivand M1, 2 ; Mousavi SR1, 2 ; Khorrami M3 ; Ayromlou H4 ; Rikhtegar R5 ; Saberi L3 ; Khademi B1, 2 ; Bahmanpour Z1, 2 ; Emamalizadeh B1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Immunology research center, Tabriz University of medical science, Tabriz, Iran
  2. 2. Department of Medical Genetics, Faculty of Medicine, Tabriz university of Medical Sciences, Tabriz, Iran
  3. 3. Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Neurology Department, Imam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran
  5. 5. Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran

Source: Journal of Neuroimmunology Published:2020


Abstract

Multiple sclerosis is immune-mediated disease of the central nervous system characterized by demyelination in axons. IFN-β is first-line treatment of MS. Biomarkers are needed for early prediction of responders and non-responders to therapy in the first month of treatment to avoid further disabilities. In this study, we analyzed the expression level of miR-504 and miR-711 in 52 IFN-β responder patients in comparison to 53 non-responders. In the next step, the in-silico analysis was used to enrich related signaling pathways. The expression level of miR-504 was significantly higher in patients who respond to IFN-β therapy, compared with non-responders and we obtain related statistically significant KEGG molecular signaling pathways. Our findings suggest that miR-504 can be considered as a novel biomarker for response to IFN-b therapy. © 2020 Elsevier B.V.
Related Docs
View other Related Docs
1. Connection of Mir-185 and Mir-320A Expression Levels With Response to Interferon-Beta in Multiple Sclerosis Patients, Multiple Sclerosis and Related Disorders (2020)
2. Mir-145 and Mir20a-5P Potentially Mediate Pleiotropic Effects of Interferon-Beta Through Mitogen-Activated Protein Kinase Signaling Pathway in Multiple Sclerosis Patients, Journal of Molecular Neuroscience (2017)
3. Comparison of the Expression of Mir-326 Between Interferon Beta Responders and Non-Responders in Relapsing-Remitting Multiple Sclerosis, Cell Journal (2020)
4. Micrornas: Key Modulators of Disease-Modifying Therapies in Multiple Sclerosis : Pancreatic Cancer Is One of the Lethal Malignant Tumours in the World.In This Study, We Investigated the Car T-Cell Therapy of Pancreatic Cancer, International Reviews of Immunology (2020)
5. The Effect of Interferon-Beta Therapy on T-Helper 17/Mir-326 and T-Helper 1/Mir-29B-3P Axis in Relapsing-Remitting Multiple Sclerosis Patients, NeuroImmunoModulation (2022)
6. Microrna-29B Variants and Mxa Expression Change During Interferon Beta Therapy in Patients With Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2019)
7. Mir-326 and Mir-26A, Two Potential Markers for Diagnosis of Relapse and Remission Phases in Patient With Relapsing-Remitting Multiple Sclerosis, Gene (2014)
8. Comparison of Expression Levels of Mir-29B-3P and Mir-326 in T Helper-1 and T Helper-17 Cells Isolated From Responsive and Non-Responsive Relapsing-Remitting Multiple Sclerosis Patients Treated With Interferon-Beta, Iranian Journal of Allergy, Asthma and Immunology (2020)
Experts (# of related papers)
View all Related Experts
Masoud Etemadifar (38)
Vahid Shaygannejad (29)
Other Related Docs
9. Mir-141 and Mir-200A, Revelation of New Possible Players in Modulation of Th17/Treg Differentiation and Pathogenesis of Multiple Sclerosis, PLoS ONE (2015)
10. Apamin Administration Impact on Mir-219 and Mir-155-3P Expression in Cuprizone Induced Multiple Sclerosis Model, Molecular Biology Reports (2020)
11. The Role of Cobalamin on Interleukin 10, Osteopontin, and Related Micrornas in Multiple Sclerosis, Iranian Journal of Allergy, Asthma and Immunology (2022)
12. Analysis of the Expression of Mir-34A, Mir-199A, Mir-30C and Mir-19A in Peripheral Blood Cd4+T Lymphocytes of Relapsing-Remitting Multiple Sclerosis Patients, Gene (2018)
13. The Effect of Beta Interferon on the Expression of Mir-145 in Patients With Multiple Sclerosis, Journal of Isfahan Medical School (2016)
14. Interdependency of Ninj2 Gene Expression and Polymorphism With Susceptibility and Response to Interferon Beta in Patients With Multiple Sclerosis, International Journal of Neuroscience (2024)
15. The Role of Micrornas Involved in the Disorder of Blood–Brain Barrier in the Pathogenesis of Multiple Sclerosis, Frontiers in Immunology (2023)
16. Study of the Correlation Between Mir-106A, Mir-125B, and Mir-330 on Multiple Sclerosis Patients by Targeting Tnfsf4 and Sp1 in Nf-Κb/Tnf-Α Pathway: A Case-Control Study, Cell Journal (2022)
17. An Integrated Bioinformatics Analysis of the Potential Regulatory Effects of Mir-21 on T-Cell Related Target Genes in Multiple Sclerosis, Avicenna Journal of Medical Biotechnology (2021)
18. Mir-195 Down-Regulation Is a Distinctive Biomarker of Her2 Positive State in Breast Cancer, Gene Reports (2020)
19. A H. Pylori-Independent Mir-21 Overexpression in Gastric Cancer Patients, Gene Reports (2019)
20. Upregulation of Cd4+ T-Cell Derived Mir-223 in the Relapsing Phase of Multiple Sclerosis Patients, Cell Journal (2016)
21. Transplantation of Human Adipose-Derived Stem Cells Overexpressing Lif/Ifn-Β Promotes Recovery in Experimental Autoimmune Encephalomyelitis (Eae), Scientific Reports (2022)
22. Systems Biology and Machine Learning Approaches Identify Drug Targets in Diabetic Nephropathy, Scientific Reports (2021)
23. Interleukin-33 Plasma Levels in Patients With Relapsing-Remitting Multiple Sclerosis, Biomolecular Concepts (2017)
24. Targetome Analysis Revealed Involvement of Mir-126 in Neurotrophin Signaling Pathway: A Possible Role in Prevention of Glioma Development, Cell Journal (2018)
25. Antibodies to Interferon Beta in Patients With Multiple Sclerosis Receiving Cinnovex, Rebif, and Betaferon, Journal of Korean Medical Science (2013)
26. Rapid Exacerbation of Multiple Sclerosis Following the Initiation of Interferon-Β: Report of Nine Cases, Journal of Research in Medical Sciences (2011)
27. Microrna-92A Drives Th1 Responses in the Experimental Autoimmune Encephalomyelitis, Inflammation (2019)
28. Comparative Analysis of Apigenin-3 Acetate Versus Apigenin and Methyl-Prednisolone in Inhibiting Proliferation and Gene Expression of Th1 Cells in Multiple Sclerosis, Cell Journal (2023)
29. Potential Biomarker and Therapeutic Lncrnas in Multiple Sclerosis Through Targeting Memory B Cells, NeuroMolecular Medicine (2020)
30. Evaluation of the Expressed Mir‑129 and Mir‑549A in Patients With Multiple Sclerosis, Advanced Biomedical Research (2021)
31. Joint Application of Magnetic Resonance Imaging and Biochemical Biomarkers in Diagnosis of Multiple Sclerosis, Current Medicinal Chemistry (2020)
32. Designing of an Elisa Method for the Measurement of Serum Antibodies Against Interferon-Beta and the Study of the Frequency of These Antibodies in Patients With Multiple Sclerosis Treated With Cinnovex, Journal of Isfahan Medical School (2012)
33. Lncrnas Associated With Multiple Sclerosis Expressed in the Th1 Cell Lineage, Journal of Cellular Physiology (2019)
34. Microrna-219 in the Central Nervous System: A Potential Theranostic Approach, Research in Pharmaceutical Sciences (2024)
35. Pure Spinal Multiple Sclerosis: A Case Series of a Possible New Entity, Journal of Neuroimmunology (2025)
36. Identification of Key Genes and Biological Regulatory Mechanisms in Diabetic Nephropathy: Meta-Analysis of Gene Expression Datasets; [Identificacion De Genes Clave Y Mecanismos Reguladores Biologicos En La Nefropatia Diabetica: Metaanalisis De Conjuntos De Datos De Expresion Genica], Nefrologia (2023)
37. Cytokine Gene Expression in Newly Diagnosed Multiple Sclerosis Patients, Iranian Journal of Allergy, Asthma and Immunology (2015)
38. Neutralizing Antibodies in Multiple Sclerosis Patients on Weekly Intramuscular Avonex and Biosimilar Interferon Beta-1A (Cinnovex): Comparing Results of Measurements in Two Different Laboratories, Journal of Immunological Methods (2013)
39. Interferon-Beta-1Beta Protects Against Multiple Sclerosis-Induced Endothelial Cells Apoptosis, Frontiers in Bioscience - Elite (2012)
40. Comparing Side Effects of Cinnovex With Avonex in Relapsing Remitting Multiple Sclerosis Patients, Journal of Isfahan Medical School (2009)
41. Increased Serum Level of Il-37 in Patients With Multiple Sclerosis and Neuromyelitis Optica, Acta Neurologica Belgica (2015)
42. The Effect of Plasma Exchange on the Expression of Foxp3 and Rorc2 in Relapsed Multiple Sclerosis Patients, Iranian Journal of Immunology (2015)
43. Semaphorin-3A As an Immune Modulator Is Suppressed by Microrna-145-5P, Cell Journal (2018)
44. First-Year Treatment Response Predicts the Following 5-Year Disease Course in Patients With Relapsing-Remitting Multiple Sclerosis, Neurotherapeutics (2025)
45. Revisiting the Antiviral Theory to Explain Interferon-Beta's Effectiveness for Relapsing Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2022)
46. Upregulation of Mtor, Rps6kb1, and Eif4ebp1 in the Whole Blood Samples of Iranian Patients With Multiple Sclerosis Compared to Healthy Controls, Metabolic Brain Disease (2020)
47. The Frequencies of Peripheral Blood Cd5+Cd19+ B Cells, Cd3−Cd16+Cd56+ Nk, and Cd3+Cd56+ Nkt Cells and Serum Interleukin-10 in Patients With Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder, Allergy, Asthma and Clinical Immunology (2022)
48. Transmembrane Signaling Molecules Play a Key Role in the Pathogenesis of Iga Nephropathy: A Weighted Gene Co-Expression Network Analysis Study, BMC Immunology (2021)
49. Identification of Potential Biomarkers in the Peripheral Blood Mononuclear Cells of Relapsing–Remitting Multiple Sclerosis Patients, Inflammation (2022)
50. Multiple Sclerosis: Clinical Features, Pathophysiology, Neuroimaging and Future Therapies, Future Neurology (2009)